EGFR and Alzheimer disease: For sPC3, AG-957 (ρ=0.3845, q=0.0043), a protein kinase inhibitor (ABL1, EGFR), SRT-1720 (ρ=0.3733, q=0.0053), a SIRT activator (SIRT1), and Fluphenazine (ρ=0.3632, q=0.0053), a dopamine receptor antagonist (DRD1, DRD2), were positively associated with the AD signatures (Figure 6A).